Compare Mesoblast Limited (MESO) vs Marqeta Inc (MQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Marqeta Inc — how do they compare? Mesoblast Limited trades at $16.74 (market cap $2.21B), while Marqeta Inc trades at $15.65 (market cap $1.62B). The key difference: Mesoblast Limited is the larger of the two by market cap, and Mesoblast Limited is trading nearer its 52-week high, Marqeta Inc nearer its low. Which is the better fit depends on your goals.
| MESO | MQ | |
|---|---|---|
Market Cap | $2.21B | $1.62B |
Sector | Technology | Technology |
52-Week High | $20.96 | $26.00 |
52-Week Low | $12.88 | $15.04 |
Enterprise Value | $2.21B | $935.36M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.78, up 0.6% with a bullish technical signal from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144% net margin. Recent milestones include Phase 3 trial completion for chronic back pain and BLA filing for heart failure treatment, indicating pipeline progress.
Investment outlook balances promising commercial traction against significant financial losses. The stock offers growth potential from expanding indications but carries high risk due to negative earnings and dependence on regulatory approvals. Analyst consensus leans bullish with 45% buy ratings, though profitability remains the key challenge.
Marqeta (MQ) trades at $15.62, up 0.13% with a bearish technical outlook. The company shows improving fundamentals with Q2 2026 revenue growth of 17% and second consecutive GAAP profitability. Recent partnerships with Google and Riskified highlight strategic expansion, while a 4:1 reverse stock split was completed in July 2026. Valuation remains elevated with a P/E of 173, though analyst consensus targets $19.00 with 32% buy ratings.
The outlook suggests cautious optimism as Marqeta transitions to profitability amid competitive fintech pressures. Key risks include execution on new initiatives and maintaining growth momentum. Upside potential exists if recent partnerships drive sustained revenue acceleration, but high valuation multiples require continued strong performance to justify.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
